Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index.
Fcγ receptor IIB
Fcγ receptor IIIA
Polymorphism
SLE disease activity index
Systemic lupus erythematous
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
18 Dec 2021
18 Dec 2021
Historique:
received:
30
04
2021
accepted:
30
11
2021
entrez:
19
12
2021
pubmed:
20
12
2021
medline:
22
12
2021
Statut:
epublish
Résumé
Systemic lupus erythematous (SLE) disease is a chronic autoimmune disease with unknown etiology that can involve different organs. Polymorphisms in Fcγ receptors have been identified as genetic factors in susceptibility to SLE. This study was aimed to investigate effects of two single nucleotide polymorphisms (SNPs) within FcγRIIB and FcγRIIIA genes on systemic lupus erythematous disease activity index (SLEDAI) in an Iranian population. Our findings indicated TT and GG genotypes were the common genotypes of FcγRIIB and FcγRIIIA SNPs in SLE patients, respectively. There were no significant differences in genotype and allele frequencies of FcγRIIB and FcγRIIIA SNPs in SLE and healthy subjects. However, the frequencies of genotypes and alleles of FcγRIIB and FcγRIIIA SNPs were significantly associated with some clinical manifestations used to determine SLEDAI (P < 0.001-0.5).
Identifiants
pubmed: 34922596
doi: 10.1186/s13104-021-05868-2
pii: 10.1186/s13104-021-05868-2
pmc: PMC8684074
doi:
Substances chimiques
FCGR2B protein, human
0
Fc gamma receptor IIA
0
Receptors, IgG
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
455Subventions
Organisme : Isfahan University of Medical Sciences
ID : 396668
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Scand J Immunol. 1995 Nov;42(5):577-80
pubmed: 7481565
J Immunol Methods. 2005 Nov 30;306(1-2):151-60
pubmed: 16219319
Rev Bras Reumatol Engl Ed. 2016 Nov - Dec;56(6):515-520
pubmed: 27914599
Arthritis Rheum. 2001 Feb;44(2):361-7
pubmed: 11229467
Rheumatology (Oxford). 2016 May;55(5):939-48
pubmed: 26748351
Arch Med Sci. 2019 Jul;15(4):872-879
pubmed: 31360182
Saudi Med J. 2004 Oct;25(10):1445-8
pubmed: 15494819
Int J Immunogenet. 2020 Feb;47(1):57-64
pubmed: 31565862
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419863238
pubmed: 31280608
Int J Immunogenet. 2019 Dec;46(6):444-450
pubmed: 31293069
Immunogenetics. 2020 May;72(4):217-224
pubmed: 32020248
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
BMC Res Notes. 2018 May 29;11(1):343
pubmed: 29843819
Mol Biol Rep. 2021 Mar;48(3):2047-2052
pubmed: 33389528
Autoimmun Rev. 2016 Jun;15(6):510-2
pubmed: 26854400
Springer Semin Immunopathol. 2006 Dec;28(4):329-38
pubmed: 17091247
Tohoku J Exp Med. 2015;236(3):185-91
pubmed: 26084639
Ann Rheum Dis. 2008 Feb;67(2):154-61
pubmed: 17557887
Medicine (Baltimore). 2019 Apr;98(14):e15030
pubmed: 30946340
Immunity. 2020 Jan 14;52(1):136-150.e6
pubmed: 31940267
Elife. 2019 Jul 25;8:
pubmed: 31343409
Ann Rheum Dis. 2002 Sep;61(9):786-92
pubmed: 12176802
Sci Rep. 2016 Aug 19;6:31617
pubmed: 27538381
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Arthritis Rheum. 2002 May;46(5):1242-54
pubmed: 12115230
Arthritis Rheum. 1992 Jun;35(6):630-40
pubmed: 1599520
Lupus. 1999;8(4):305-10
pubmed: 10413210
Rheumatol Int. 2017 Apr;37(4):523-529
pubmed: 28184992
Nat Rev Immunol. 2002 Aug;2(8):580-92
pubmed: 12154377
Eur J Immunogenet. 2002 Aug;29(4):301-6
pubmed: 12121275
Nat Commun. 2019 Apr 29;10(1):1970
pubmed: 31036800
Indian J Med Res. 2011 Aug;134:181-5
pubmed: 21911970
Hum Mutat. 2009 Mar;30(3):477-84
pubmed: 19143032
J Dermatol Sci. 2006 Jul;43(1):35-41
pubmed: 16531013
Genes Immun. 2019 Jul;20(6):493-499
pubmed: 30245507
Lupus. 1998;7(9):585-90
pubmed: 9884094
Clin Exp Med. 2014 Aug;14(3):269-74
pubmed: 23708937
Rheumatology (Oxford). 2004 May;43(5):547-54
pubmed: 14747618